MAP hydrogel biodegradation enhances stem cell growth
A study showed that bone stem cells rearrange degrading microporous annealed particle (MAP) hydrogels, promoting their growth.
List view / Grid view
A study showed that bone stem cells rearrange degrading microporous annealed particle (MAP) hydrogels, promoting their growth.
Out of specification results from stability studies have led Glenmark Pharmaceuticals to recall batches of their iohexol solution for injection in the UK.
The US FDA has approved AUDENZ, a vaccine formulated with MF59® adjuvant, as an Influenza A H5N1 vaccine that can be quickly deployed in the event of a pandemic.
The EMA has released a statement on its efforts to support the development of a treatment for the novel coronavirus (2019-nCoV).
A patch the size of a coin has been created by researchers as a way to detect glucose levels in the blood and deliver insulin when required.
The US NIAID has stopped its HVTN 702 clinical trial for an HIV vaccine after an independent board found that the treatment did not prevent the condition.
An innovation in hydrogels has created a portable, reusable chemical-producing platform that could provide access to essential pharmaceuticals without specialised storage requirements.
The UK Health Secretary announced the government will give Coalition for Epidemic Preparedness Innovations (CEPI) £20 million to research vaccines for the 2019 novel coronavirus (2019-nCoV).
Palforzia, a peanut allergen powder, has been approved for the reduction of allergic reactions in children aged four to 17. It is not an emergency treatment but instead designed to build tolerance.
Johnson & Johnson announced Janssen Pharmaceutical Companies will work collaboratively to screen for antiviral therapies and vaccine therapies against 2019-nCoV.
Esketamine nasal spray did not receive a positive opinion from NICE due to inadequate comparisons to other therapies and concerns over its cost effectiveness.
In a bid to address an unmet clinical need for patients in Japan, roxadustat has been presented as a potential treatment for a particular kind of anaemia.
Research has developed bandages which change colour and release antibiotics and/or reactive oxygen species in response to an infected wound which could curb the spread of antibiotic resistance.
As companies continue to collaborate and share their expertise to develop therapeutics targeting a wide range of diseases, European Pharmaceutical Review explores the aims of the most recent partnerships.
Mayzent (siponimod) has been approved by the European Commission (EC) for adults with secondary progressive multiple sclerosis (SPMS) based on the results of the EXPAND trial.